Oncotarget

Research Papers:

A novel Mcl1 variant inhibits apoptosis via increased Bim sequestration

Judith Hagenbuchner _, Ursula Kiechl-Kohlendorfer, Petra Obexer and Michael J. Ausserlechner

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2013; 4:1241-1252. https://doi.org/10.18632/oncotarget.1147

Metrics: PDF 1453 views  |   HTML 1494 views  |   ?  


Abstract

Judith Hagenbuchner1,3, Ursula Kiechl-Kohlendorfer1, Petra Obexer1,3, Michael J. Ausserlechner2,3

1 Department of Pediatrics II, Medical University Innsbruck, Austria

2 Department of Pediatrics I, Medical University Innsbruck, Austria

3 Tyrolean Cancer Research Institute, Innsbruck, Austria

Correspondence:

Petra Obexer, email:

Michael Ausserlechner, email:

Keywords: Mcl1L, apoptosis, BCL2 proteins, mRNA variant

Received: July 1, 2013 Accepted: July 13, 2013 Published: July 15, 2013

Abstract

Members of the Bcl-2 protein family are frequently deregulated in tumors as they critically control cell death induction in mammalian cells. Alterations of these proteins may cause resistance to chemotherapy-induced cell death and immune responses. By serendipity we cloned a variant of the anti-apoptotic Bcl2-family member Myeloid cell leukemia-1 (Mcl1) from human neuroblastoma and leukemia cells. This Mcl1L variant lacks a 45 bp sequence that codes for 15 highly conserved amino acids ranging from Gly158 to Asp172. This region is part of the so called PEST-sequence of Mcl1L and contains two phosphorylation sites (Ser159 and Thr163) that regulate Mcl1L stability. A caspase 3/caspase 8 cleavage site at Asp157 which has been reported to be critical for death-receptor-induced apoptosis and for the conversion of Mcl1L into a pro-apoptotic protein is also missing in this novel variant. Importantly, Mcl1LdelGly158-Asp172 bound significantly more pro-apoptotic Bim compared to Mcl1L and showed increased anti-proliferative and anti-apoptotic activity compared to Mcl1L during death receptor-induced cell death. This suggests that this novel Mcl1L variant efficiently protects tumor cells against extrinsic death signalling and therefore may provide a survival advantage for highly aggressive tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1147